Cytokine storm and use of anakinra in a patient with COVID-19

BMJ Case Rep. 2020 Sep 15;13(9):e237525. doi: 10.1136/bcr-2020-237525.

Abstract

We present a case of a 50-year-old man with COVID-19 infection and acute respiratory distress syndrome as a result of a cytokine storm and use of anakinra, an interleukin 1-receptor antagonist that is normally used in the treatment of autoinflammatory disorders in adult patients. We saw a reduction in oxygen requirement and improvements in inflammatory markers and ferritin. Although we cannot determine its clinical efficacy from one case study, it may have a positive effect on the proinflammatory state that is associated with cytokine storm in COVID-19 infection.

Keywords: immunological products and vaccines; immunology; infections; infectious diseases; musculoskeletal and joint disorders.

Publication types

  • Case Reports

MeSH terms

  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology*
  • Cytokines / physiology*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology*
  • Severity of Illness Index

Substances

  • Cytokines
  • Interleukin 1 Receptor Antagonist Protein